RedHill Biopharma files prospectus supplement to increase ATM offering with H.C. Wainwright
On October 13, 2026, RedHill Biopharma Ltd. filed a prospectus supplement to increase the maximum aggregate offering amount of American Depositary Shares (each representing 10,000 ordinary shares) that may be issued and sold from time to time under the At The Market Offering Agreement with H.C. Wainwright & Co., LLC dated February 3, 2025. Each Placement ADS represents 10,000 ordinary shares, no par value. The placement ADSs are offered under the Company's Form F-3 registration statement (No. 333-281417), and th...
Key takeaways
ATM offering size: Aggregate offering price of up to $2,587,409 in Placement ADSs, with each ADS representing 10,000 ordinary shares of the Company.
Sales agent: H.C. Wainwright & Co., LLC under the At The Market Offering Agreement originally dated February 3, 2025.
Registration basis: Form F-3 (Registration No. 333-281417), originally filed August 9, 2024 and declared effective August 19, 2024; prior prospectus supplements dated February 3, 2025, November 26, 2025, May 7, 2026, and June 29, 2026.
Legal opinions: Goldfarb Gross Seligman & Co. (Israeli counsel) and Haynes and Boone, LLP (U.S. counsel) delivered opinions as Exhibits 5.1 and 5.2.
Depositary: The Bank of New York Mellon under the Deposit Agreement dated December 26, 2012.
Filing status: Report on Form 6-K furnished by RedHill Biopharma as a foreign private issuer; the Form 6-K is incorporated by reference into existing Form S-8 and Form F-3 registration statements.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow RDHL in real time
Get material earnings, filing, IR, and earnings-call alerts by email.